GPCR NewsJun 1, 20221 minGPCR Industry NewsNeurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital ...June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO...
GPCR NewsJan 1, 20221 minGPCR Industry NewsLearn more about Neurocrine Biosciences with their new videoJanuary 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special. It...
GPCR NewsJan 1, 20221 minGPCR Industry NewsLearn more about Neurocrine Biosciences with their new videoJanuary 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special. It...
GPCR NewsDec 1, 20211 minGPCR Industry NewsSosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine BiosciencesDecember 2021 "Tokyo, Japan and Cambridge, UK, 24 December 2021 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces...
GPCR NewsDec 1, 20211 minGPCR Industry NewsNeurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated...
GPCR NewsNov 1, 20211 minGPCR Industry NewsCalifornia gold rush for Sosei HeptaresNovember 2021 "Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal with California-based...